Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 28 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1905 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Valeant Pharmaceuticals International has acquired US rights to the capsule and gel formulations of Targretin® (bexarotene), which is used to treat skin problems arising from cutaneous T-cell lymphoma, from Eisai for US$65 M upfront plus contingent payments based on certain undisclosed milestones...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS